38.39
0.00%
Close of 9 Nov 2026, in CNY
Search any instrument
Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.
About BGI Genomics Co
Its shares trade on Shenzhen under the ticker 300676.SZ. It has been listed since 14 July 2017. In the fiscal year to 31 December 2025, it reported revenue of CN¥3.71bn and a net loss of CN¥616.7m. At that date it held total assets of CN¥11.75bn and shareholders' equity of CN¥8.49bn.
BGI Genomics Co., Ltd. is a holding company that engages in development of science and technology services in genomics field. The company is headquartered in Shenzhen, Guangdong. The company went IPO on 2017-07-14. The firm's main products and services include reproductive health basic research and clinical application services, basic science research services (genome sequencing, bioinformatics analysis and other multithreaded solutions), complex disease basic research and clinical application services, as well as drugs basic research and clinical application services. The firm mainly provides services for domestic and overseas academic institutions, research institutes, independent laboratories, pharmaceutical companies, hospitals and medical institutions, among others. The firm mainly operates its businesses in domestic market.
Figures and description from our data supplier, not checked against the company's own report.
Company facts
- Sector
- Health Care
- Industry
- Biotechnology
- Listed since
- 14 Jul 2017
- Employees
- 4,448
- Website
- bgi.com ↗
Leadership
Pay as last reported
- Mr. Jian WangChairman of the Board, since 2015
- Mr. Yujue WangChief Financial Officer, Deputy General Manager, Director, since 2021CN¥1.3m
- Ms. Qian XuGeneral Counsel, Deputy General Manager, Secretary of the BoardCN¥1.4m
- Mr. Lijian ZhaoGeneral Manager, Director, since 2021CN¥2.1m
- Mr. Ning LiDeputy General Manager, Director, since 2021CN¥1.4m
- Mr. Shida ZhuDeputy General Manager, Director, since 2021CN¥1.5m
- Mr. Hao LiDeputy General ManagerCN¥496,500
- Ms. Yun YangDeputy General ManagerCN¥495,900
- Mr. Guocheng ZhangDirectorCN¥541,300
- Ms. Lan DuIndependent DirectorCN¥252,000
- Mr. Zhibo HouIndependent DirectorCN¥131,700
- Mr. Lisheng YuIndependent DirectorCN¥252,000
Environmental, social and governance
Scores out of 100, from our data supplier
- Overall
- 63
- Environment
- 58
- Social
- 99
- Governance
- 32
- Women in the workforce
- 56.72609%
- Carbon reduction policy
- Yes
- Human rights policy
- Yes
SWOT analysis
AI-generated by our data supplier. Not written or checked by our editors.
Strengths
- BGI Genomics Co Ltd employs 4,448 full-time employees to support its operations in Shenzhen.
- The company offers genome sequencing and bioinformatics analysis as part of its basic science research services.
- BGI Genomics serves pharmaceutical companies and hospitals in addition to academic institutions and research institutes.
Weaknesses
- The firm mainly operates its businesses in the domestic market within China.
- BGI Genomics Co Ltd went public on July 14, 2017, which is a relatively recent listing event.
- The company is headquartered in Shenzhen, Guangdong, limiting its physical presence to this specific location.
Opportunities
- The company provides reproductive health basic research and clinical application services to expand its service portfolio.
- BGI Genomics offers complex disease basic research and clinical application services to address diverse medical needs.
- The firm provides drugs basic research and clinical application services to engage with the pharmaceutical industry.
Threats
- BGI Genomics Co Ltd operates in the Biotechnology industry within the Health Care sector.
- The company relies on independent laboratories and medical institutions as key clients for its services.
- BGI Genomics provides multithreaded solutions that require continuous technological development and maintenance.
Sources and methodology
- Data on this tab
- Our data supplier
- Chart on the Overview
- TradingView
Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.